✅ Model Answer:
• Proximally pointed and tapering (bullet-shaped) metacarpals.
• Irregular, shortened metacarpal bones – proximal ends are pointed.
• Wide phalanges with constricted diaphyses ("oar-shaped" appearance).
• Delayed carpal bone ossification – few carpal bones for age.
• Dysostosis multiplex – generalized skeletal dysplasia pattern.
• Diagnosis: Mucopolysaccharidosis (likely MPS I-H, MPS II, or MPS VI).

✅ Model Answer:
• Bullet-shaped metacarpals: Metacarpal bones that are proximally pointed and tapered, giving them a bullet-like appearance.
• Mechanism: In MPS, accumulation of glycosaminoglycans (GAGs) in bones → impaired endochondral ossification → skeletal dysplasia.
• The proximal ends of the metacarpals fail to develop normally, becoming pointed instead of rounded.
• This is a classic feature of MPS (especially MPS I, II, and VI).
• Part of the dysostosis multiplex pattern of skeletal involvement.

✅ Model Answer:
• Dysostosis multiplex is a characteristic skeletal dysplasia seen in mucopolysaccharidoses.
• Features:
1. Skull: Large, J-shaped sella turcica, thickened calvarium.
2. Spine: Ovoid/platyspondyly (flattened vertebral bodies), kyphosis (gibbus).
3. Ribs: Thickened, paddle-shaped, "oar-like" ribs.
4. Pelvis: Hypoplastic iliac bones, shallow acetabula.
5. Long bones: Thickened cortices, diaphyseal widening.
6. Hands: Bullet-shaped metacarpals, wide phalanges, delayed carpal ossification.
7. Clavicles: Thickened.
• It reflects the lysosomal storage of GAGs in bone and cartilage.

✅ Model Answer:
• Coarse facial features: Thick eyebrows, flat nasal bridge, enlarged lips, macroglossia.
• Skeletal: Dysostosis multiplex – short stature, joint stiffness, claw hand, carpal tunnel syndrome.
• Organomegaly: Hepatosplenomegaly (MPS I, II, III, VI, VII).
• Neurological: Developmental delay, intellectual disability (variable), hydrocephalus (MPS I, II).
• Ocular: Corneal clouding (MPS I, IV, VI; absent in MPS II).
• Cardiac: Valvular heart disease, cardiomyopathy (MPS I, II, VI).
• Hearing: Sensorineural hearing loss (MPS I, II, VI).
• Airway: Obstructive sleep apnea, recurrent infections.

✅ Model Answer:

MPS Type	Enzyme Deficiency	Key Features
MPS I (Hurler)	α-L-iduronidase	Severe cognitive impairment, corneal clouding, dysostosis multiplex
MPS II (Hunter)	Iduronate sulfatase	X-linked, clear corneas, mild/moderate cognitive impairment
MPS III (Sanfilippo)	Heparan N-sulfatase (etc.)	Severe neurological regression, mild somatic findings
MPS IV (Morquio)	Galactosamine-6-sulfatase	Skeletal dysplasia (odontoid hypoplasia), normal intelligence
MPS VI (Maroteaux-Lamy)	Arylsulfatase B	Dysostosis multiplex, normal intelligence, corneal clouding
MPS VII (Sly)	β-glucuronidase	Dysostosis multiplex, hepatosplenomegaly, hydrops fetalis

✅ Model Answer:
• Screening:
- Urine GAGs (glycosaminoglycans): Elevated heparan sulfate, dermatan sulfate, keratan sulfate (depends on type).
- Quantitative and qualitative analysis (GAG electrophoresis).
• Confirmatory:
- Enzyme assay: Specific enzyme activity in leukocytes or fibroblasts (e.g., α-L-iduronidase for MPS I).
- Genetic testing: Mutation analysis (e.g., IDUA for MPS I, IDS for MPS II).
• Imaging:
- Skeletal survey (dysostosis multiplex).
- MRI brain (hydrocephalus, white matter changes).
• Other:
- Echocardiogram (valvular disease).
- Ophthalmology (corneal clouding).
- Audiology (hearing loss).
- Pulmonary function tests (restrictive lung disease).

✅ Model Answer:
• Enzyme Replacement Therapy (ERT):
- Laronidase (MPS I), Elosulfase alfa (MPS IV), Galsulfase (MPS VI), Idursulfase (MPS II).
- Reduces somatic symptoms, improves joint mobility, pulmonary function.
- Does NOT cross the blood-brain barrier (limited effect on CNS).
• Hematopoietic Stem Cell Transplantation (HSCT):
- For MPS I-H (Hurler) – best outcomes if performed early (<2 years).
- Can improve CNS outcomes and skeletal disease.
• Supportive care:
- Orthopedic surgery (joint contractures, hip dysplasia).
- Carpal tunnel release.
- Cardiac valve replacement.
- Spinal decompression (cervical instability).
- Airway management (CPAP, tracheostomy).
- Physical therapy, occupational therapy, speech therapy.
- Genetic counseling.

✅ Model Answer:
• Corneal clouding is a classic feature of MPS I (Hurler) and MPS VI (Maroteaux-Lamy).
• It is caused by accumulation of GAGs in the corneal stroma.
• Significance:
- Can cause photophobia, decreased visual acuity, and blindness.
- Presence of corneal clouding helps differentiate MPS I from MPS II (Hunter) – which has clear corneas.
• Management:
- Corneal transplantation (penetrating keratoplasty) – may improve vision if significant.
- ERT may slow progression but does not reverse existing clouding.
- Regular ophthalmology follow-up.

✅ Model Answer:
• ERT does not cross the blood-brain barrier (BBB).
• The enzyme is too large (high molecular weight) to pass through the BBB.
• Therefore, ERT does not treat CNS manifestations (cognitive decline, hydrocephalus, spinal cord compression).
• HSCT can cross the BBB and provide CNS benefit (if performed early, <2 years of age).
• Intrathecal ERT is being studied in clinical trials but is not yet standard.
• Supportive care: Seizure management, cognitive rehabilitation, hydrocephalus treatment (VP shunt).

✅ Model Answer:
• This is MPS I-H (Hurler syndrome) – severe phenotype with cognitive decline.
• Management:
1. Confirm diagnosis: Enzyme assay (α-L-iduronidase) and genetic testing (IDUA).
2. Hematopoietic stem cell transplantation (HSCT): Best outcomes if performed <2 years.
3. Enzyme replacement therapy (laronidase): If HSCT is not possible, ERT can be used for somatic symptoms.
4. Supportive care: Seizure management, hydrocephalus monitoring (VP shunt), orthopedic interventions.
5. Multidisciplinary team: Metabolic, neurology, orthopedics, ophthalmology, cardiology.
6. Genetic counseling: Autosomal recessive inheritance.

✅ Model Answer:

Feature	MPS I (Hurler)	MPS II (Hunter)
Inheritance	Autosomal recessive	X-linked
Corneal clouding	Yes	No (clear corneas)
Cognitive decline	Severe	Variable (mild to severe)
Enzyme deficiency	α-L-iduronidase	Iduronate sulfatase
Gene	IDUA	IDS